The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is ...

RBC Capital Markets initiated coverage on Tandem Diabetes Care ... the rise of GLP-1s class drugs is not a major threat to insulin pump adoption. GLP-1 drugs such as Novo Nordisk A/S‘ (NYSE ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) ...

RBC expects 51% gross margins in 2024, with the Mobi pump launch driving long-term profitability. RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. TNDM, a global insulin ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery ...

Tandem Diabetes Care has announced that its t:slim X2 insulin pump, featuring Control-IQ automated insulin delivery technology, received approval for use with the ultra-rapid-acting insulin ...

SAN DIEGO, September 19, 2024--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump ...

RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin ...